Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.

Demeyer A, Skordos I, Driege Y, Kreike M, Hochepied T, Baens M, Staal J, Beyaert R.

Front Immunol. 2019 Aug 14;10:1898. doi: 10.3389/fimmu.2019.01898. eCollection 2019.

2.

Inhibition of MALT1 Decreases Neuroinflammation and Pathogenicity of Virulent Rabies Virus in Mice.

Kip E, Staal J, Tima HG, Verstrepen L, Romano M, Lemeire K, Suin V, Hamouda A, Baens M, Libert C, Kalai M, Van Gucht S, Beyaert R.

J Virol. 2018 Oct 29;92(22). pii: e00720-18. doi: 10.1128/JVI.00720-18. Print 2018 Nov 15.

3.

Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Baens M, Stirparo R, Lampi Y, Verbeke D, Vandepoel R, Cools J, Marynen P, de Bock CE, Bornschein S.

Eur J Immunol. 2018 Oct;48(10):1728-1738. doi: 10.1002/eji.201847597. Epub 2018 Aug 7.

4.

MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.

Baens M, Bonsignore L, Somers R, Vanderheydt C, Weeks SD, Gunnarsson J, Nilsson E, Roth RG, Thome M, Marynen P.

PLoS One. 2014 Aug 8;9(8):e103774. doi: 10.1371/journal.pone.0103774. eCollection 2014.

5.

The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.

Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM.

Oncogene. 2014 May 8;33(19):2520-30. doi: 10.1038/onc.2013.195. Epub 2013 Jun 17.

6.

Recurrent breakpoints in 14q32.13/TCL1A region in mature B-cell neoplasms with villous lymphocytes.

Urbankova H, Baens M, Michaux L, Tousseyn T, Rack K, Katrincsakova B, Ferreiro JF, van Loo P, de Kelver W, Dierickx D, Demuynck H, Delannoy A, Verschuere J, Jarošová M, de Wolf-Peeters C, Vandenberghe P, Wlodarska I.

Leuk Lymphoma. 2012 Dec;53(12):2449-55. doi: 10.3109/10428194.2012.690098.

PMID:
22553924
7.

t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34.

Baens M, Finalet Ferreiro J, Tousseyn T, Urbankova H, Michaux L, de Leval L, Dierickx D, Wolter P, Sagaert X, Vandenberghe P, De Wolf-Peeters C, Wlodarska I.

Haematologica. 2012 Feb;97(2):184-8. doi: 10.3324/haematol.2011.052639. Epub 2011 Nov 4.

8.

MALT1 protease: a new therapeutic target in B lymphoma and beyond?

McAllister-Lucas LM, Baens M, Lucas PC.

Clin Cancer Res. 2011 Nov 1;17(21):6623-31. doi: 10.1158/1078-0432.CCR-11-0467. Epub 2011 Aug 25. Review.

9.

T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status.

Sagaert X, Maes B, Vanhentenrijk V, Baens M, Van Cutsem E, Hertogh GD, Geboes K, Tousseyn T.

World J Gastrointest Oncol. 2011 Feb 15;3(2):24-32. doi: 10.4251/wjgo.v3.i2.24.

10.

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.

11.

DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma.

Lee S, Syed N, Taylor J, Smith P, Griffin B, Baens M, Bai M, Bourantas K, Stebbing J, Naresh K, Nelson M, Tuthill M, Bower M, Hatzimichael E, Crook T.

Br J Cancer. 2010 Jul 13;103(2):265-74. doi: 10.1038/sj.bjc.6605711. Epub 2010 Jun 15.

12.

Comparative expressed sequence hybridization studies of t(11;18)(q21;q21)-positive and -negative gastric MALT lymphomas reveal both unique and overlapping gene programs.

Sagaert X, Tousseyn T, Vanhentenrijk V, Van Loo P, Baens M, Marynen P, De Hertogh G, Geboes K, De Wolf-Peeters C.

Mod Pathol. 2010 Mar;23(3):458-69. doi: 10.1038/modpathol.2009.182. Epub 2010 Jan 15.

13.

A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.

Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D.

J Immunol. 2009 Jun 15;182(12):7718-28. doi: 10.4049/jimmunol.0803313.

14.

Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.

Noels H, Somers R, Liu H, Ye H, Du MQ, De Wolf-Peeters C, Marynen P, Baens M.

PLoS One. 2009;4(3):e4822. doi: 10.1371/journal.pone.0004822. Epub 2009 Mar 12.

15.

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.

Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R.

Nat Immunol. 2008 Mar;9(3):263-71. doi: 10.1038/ni1561. Epub 2008 Jan 27.

PMID:
18223652
16.

Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL.

Pospisilova H, Baens M, Michaux L, Stul M, Van Hummelen P, Van Loo P, Vermeesch J, Jarosova M, Zemanova Z, Michalova K, Van den Berghe I, Alexander HD, Hagemeijer A, Vandenberghe P, Cools J, De Wolf-Peeters C, Marynen P, Wlodarska I.

Leukemia. 2007 Sep;21(9):2079-83. Epub 2007 May 24. No abstract available.

PMID:
17525729
17.

A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome.

La Starza R, Rosati R, Roti G, Gorello P, Bardi A, Crescenzi B, Pierini V, Calabrese O, Baens M, Folens C, Cools J, Marynen P, Martelli MF, Mecucci C, Cuneo A.

Leukemia. 2007 Apr;21(4):830-3. Epub 2007 Feb 15. No abstract available.

PMID:
17301821
18.

A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.

Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P, Baens M.

J Biol Chem. 2007 Apr 6;282(14):10180-9. Epub 2007 Feb 7.

19.

The pathogenesis of MALT lymphomas: where do we stand?

Sagaert X, De Wolf-Peeters C, Noels H, Baens M.

Leukemia. 2007 Mar;21(3):389-96. Epub 2007 Jan 18. Review.

PMID:
17230229
20.

The dark side of EGFP: defective polyubiquitination.

Baens M, Noels H, Broeckx V, Hagens S, Fevery S, Billiau AD, Vankelecom H, Marynen P.

PLoS One. 2006 Dec 20;1:e54.

21.

Splenic marginal zone lymphoma-like features in API2-MALT1 transgenic mice that are exposed to antigenic stimulation.

Sagaert X, Theys T, De Wolf-Peeters C, Marynen P, Baens M.

Haematologica. 2006 Dec;91(12):1693-6.

22.

Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination.

Baens M, Fevery S, Sagaert X, Noels H, Hagens S, Broeckx V, Billiau AD, De Wolf-Peeters C, Marynen P.

Cancer Res. 2006 May 15;66(10):5270-7.

23.

cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.

Hu S, Du MQ, Park SM, Alcivar A, Qu L, Gupta S, Tang J, Baens M, Ye H, Lee TH, Marynen P, Riley JL, Yang X.

J Clin Invest. 2006 Jan;116(1):174-81.

24.

MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells.

Sagaert X, Laurent M, Baens M, Wlodarska I, De Wolf-Peeters C.

Mod Pathol. 2006 Feb;19(2):225-32.

25.

MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation.

Hoornaert I, Marynen P, Goris J, Sciot R, Baens M.

Oncogene. 2003 Oct 30;22(49):7728-36.

PMID:
14586399
26.

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.

De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A, Poppe B, Laureys G, Brons P, Vandenberghe P, Speleman F, Praet M, De Wolf-Peeters C, Marynen P, Wlodarska I.

Blood. 2003 Oct 1;102(7):2638-41. Epub 2003 May 15.

PMID:
12750159
27.

The novel t(11;12;18)(q21;q13;q21) represents a variant translocation of the t(11;18)(q21;q21) associated with MALT-type lymphoma.

Dierlamm J, Murga Penas EM, Daibata M, Tagushi H, Hinz K, Baens M, Cools J, Schilling G, Michaux L, Marynen P, Miyoshi I, Hossfeld DK.

Leukemia. 2002 Sep;16(9):1863-4. No abstract available.

28.

Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia.

Hetet G, Dastot H, Baens M, Brizard A, Sigaux F, Grandchamp B, Stern MH.

Hematol J. 2000;1(1):42-7.

PMID:
11920168
29.

A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.

Demunter A, Ahmadian MR, Libbrecht L, Stas M, Baens M, Scheffzek K, Degreef H, De Wolf-Peeters C, van Den Oord JJ.

Cancer Res. 2001 Jun 15;61(12):4916-22.

30.

Structure of the MLT gene and molecular characterization of the genomic breakpoint junctions in the t(11;18)(q21;q21) of marginal zone B-cell lymphomas of MALT type.

Baens M, Steyls A, Dierlamm J, De Wolf-Peeters C, Marynen P.

Genes Chromosomes Cancer. 2000 Dec;29(4):281-91.

PMID:
11066071
31.

Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes.

Dierlamm J, Baens M, Stefanova-Ouzounova M, Hinz K, Wlodarska I, Maes B, Steyls A, Driessen A, Verhoef G, Gaulard P, Hagemeijer A, Hossfeld DK, De Wolf-Peeters C, Marynen P.

Blood. 2000 Sep 15;96(6):2215-8.

PMID:
10979968
32.
33.

The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation.

Baens M, Maes B, Steyls A, Geboes K, Marynen P, De Wolf-Peeters C.

Am J Pathol. 2000 Apr;156(4):1433-9.

34.

Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions.

Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K, Baens M, Collen D, Schuh AC.

Blood. 2000 Feb 15;95(4):1435-42.

PMID:
10666222
35.

The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas.

Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H, Marynen P.

Blood. 1999 Jun 1;93(11):3601-9.

PMID:
10339464
36.
37.

Rearrangement between the MYH11 gene at 16p13 and D12S158 at 12p13 in a case of acute myeloid leukemia M1 (AML-M1).

La Starza R, Wlodarska I, Matteucci C, Falzetti D, Baens M, Martelli MF, Van den Berghe H, Marynen P, Mecucci C.

Genes Chromosomes Cancer. 1998 Sep;23(1):10-5.

PMID:
9713991
38.

CREBL2, a novel transcript from the chromosome 12 region flanked by ETV6 and CDKN1B.

Hoornaert I, Marynen P, Baens M.

Genomics. 1998 Jul 1;51(1):154-7. No abstract available.

PMID:
9693048
39.

Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies.

Wlodarska I, La Starza R, Baens M, Dierlamm J, Uyttebroeck A, Selleslag D, Francine A, Mecucci C, Hagemeijer A, Van den Berghe H, Marynen P.

Blood. 1998 Feb 15;91(4):1399-406.

PMID:
9454771
40.

A human homologue (BICD1) of the Drosophila bicaudal-D gene.

Baens M, Marynen P.

Genomics. 1997 Nov 1;45(3):601-6.

PMID:
9367685
41.

Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P.

Blood. 1997 Oct 1;90(7):2535-40.

PMID:
9326218
42.

Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.

Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, Marynen P.

Cancer Res. 1997 Feb 15;57(4):564-9.

43.

ETV6 gene rearrangements in hematopoietic malignant disorders.

Wlodarska I, Mecucci C, Baens M, Marynen P, van den Berghe H.

Leuk Lymphoma. 1996 Oct;23(3-4):287-95. Review.

PMID:
9031109
44.

Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes.

Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CD, Dainton M, Dyer M, Fuzibet JG, Gratecos N, Taillan B, Ayraud N, Marynen P.

Blood. 1996 Jul 15;88(2):682-9.

PMID:
8695816
45.

Biallelic alterations of both ETV6 and CDKN1B genes in a t(12;21) childhood acute lymphoblastic leukemia case.

Wlodarska I, Baens M, Peeters P, Aerssens J, Mecucci C, Brock P, Marynen P, Van den Berghe H.

Cancer Res. 1996 Jun 1;56(11):2655-61.

46.

Genomic organization of TEL: the human ETS-variant gene 6.

Baens M, Peeters P, Guo C, Aerssens J, Marynen P.

Genome Res. 1996 May;6(5):404-13.

47.

The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia.

Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux C, Guo C, Vilmer E, Marynen P, Grandchamp B.

Blood. 1996 Apr 1;87(7):2891-9.

PMID:
8639909
48.

Isolation and regional assignment of human chromosome 12p cDNAs.

Baens M, Aerssens J, van Zand K, Van den Berghe H, Marynen P.

Genomics. 1995 Sep 1;29(1):44-52.

PMID:
8530100
49.

Mapping of an ordered set of 14 cosmids to human chromosome 12p by two-color in situ hybridization.

Chaffanet M, Baens M, Aerssens J, Schoenmakers E, Cassiman JJ, Marynen P.

Cytogenet Cell Genet. 1995;69(1-2):27-32.

PMID:
7835081
50.

A physical map of the region spanning the chromosome 12 translocation breakpoint in a mesothelioma with a t(X;12)(q22;p13).

Aerssens J, Guo C, Vermeesch J, Baens M, Browne D, Litt M, Van Den Berghe H, Marynen P.

Cytogenet Cell Genet. 1995;71(3):268-75.

PMID:
7587392

Supplemental Content

Support Center